Introduction
Metabolic syndrome (MetS) is a constellation of metabolic and nonmetabolic abnormalities frequently seen among kidney transplant patients [1, 2] . The presence of MetS is associated with inferior transplant outcomes including increased risks of new-onset diabetes mellitus after transplantation (NODAT) and cardiovascular events (CVEs), and diminished kidney transplant and patient survival [1] [2] [3] [4] .
Vitamin D deficiency and insufficiency are common in both the general and kidney transplant population and are associated with an increased risk of diabetes mellitus and cardiovascular diseases and MetS [5] [6] [7] [8] . Adiponectin is a protein secreted exclusively by adipocytes and plays an important role in modulating insulin sensitivity, thus the risk of type 2 diabetes (T2D) [9] . Low levels of adiponectin have been also associated with glucose intolerance, T2D, early CVEs and MetS [10] [11] [12] [13] [14] . It is not known whether there is any relationship between vitamin D de-ficiency/insufficiency and reduced adiponectin levels. We performed a prospective cohort study to elucidate the relationship between vitamin D deficiency/insufficiency, hypoadiponectinemia and MetS early after kidney transplantation, as well as their impact on overall clinical outcomes among previously nondiabetic kidney transplant patients.
Materials and Methods
Between February and November 2008, de novo kidney transplant patients without a history of diabetes prior to transplantation were enrolled in a prospective cohort study. Study participants underwent a protocol-driven 2-hour oral glucose tolerance test between weeks 10-14 post-transplantation [15] . Fasting blood plasma was collected and stored at -80 ° C. The local institutional review board approved the study.
Anthropometric parameters and baseline demographic and clinical information obtained at the time the oral glucose tolerance test was performed included height, body weight and waist circumference, BMI, blood pressure readings and the numbers of antihypertensive medications, age, gender, racial/ethnicity, renal diagnosis, family history of T2D, previous history of cardiovascular disease, the use of dialysis modalities and the duration of dialysis prior to transplantation, type of kidney transplant, number of kidney transplants, status of hepatitis C serology, the presence of delayed graft function, maintenance immunosuppression regimens, and cumulative doses of corticosteroids and calcinuerin inhibitors (CNIs) up to the time of the oral glucose tolerance test. During subsequent follow-up to December 31, 2012, the clinical events including the occurrence of CVEs, new-onset diabetes mellitus after transplantation, acute rejection (AR) and kidney graft loss (including death) were documented, and final transplant function, expressed as estimated glomerular filtration rate using an abbreviated Modification of Diet in Renal Disease (MDRD) formula, was recorded.
MetS was defined according to the criteria established by the National Cholesterol Education Expert Panel III (NCEP-III) and present if a participant had at least 3 of following 5 components: fasting glucose levels of 100 mg/dl or greater, fasting triglyceride values of 150 mg/dl or greater, HDL cholesterol (HDL-C) levels of less than 40 mg/dl for males or 50 mg/dl for females, blood pressure equal or greater than 130/85 mm Hg or on antihypertensive medications, and waist circumference equal or greater than 40 and 35 inches (101.6 and 88.9 cm) for males and females, respectively [16] . Continuous and categorical variables were compared using Student's t test and χ 2 test, respectively. Multivariate regression analyses were utilized to test the association between the presence of MetS and various measured parameters including plasma 25 [OH]D and adiponectin levels among others, and to correlate them with observed clinical outcomes (composite). All statistical analyses were performed using SAS 9.3. Statistical significance was set at p ≤ 0.05.
Results
There were 74 study participants with a median follow-up of 4.27 years (3.99, 4.46). The mean age was 46 ± 16 years, 50 (67.6%) were male patients and 22 (29.7%) of African-American race. The prevalence of MetS was 45.9% (n = 34) at a median time of 79 days (71, 89) posttransplantation. Table 1 shows the demographic and baseline characteristics of study participants with and Adiponectin, an adipose-tissue derived plasma protein, has been implicated in the homeostasis of glucose metabolism and IR [10, 11] . We measured plasma adiponectin levels among the study participants. Patients with MetS had significantly lower levels of plasma adiponectin compared to patients without MetS (8.2 ± 4.5 vs. 14.6 ± 8.0 μg/ml, p < 0.0001) ( fig. 2 a) . Stepwise multivariate regression analysis confirmed a statistically significant negative association between either the presence of MetS or the numbers of MetS components and plasma adiponectin concentration (β estimate -6.39 and -3.27, r 2 0.195 and 0.163, p < 0.0001 and p = 0.0004, respectively) ( fig. 2 b) . Other variables associated with low plasma adiponectin concentration included male gender and African-American race (β estimate -4.29 and -3. immunosuppressive drugs (neither the type of CNIs nor the cumulative doses of CNIs and corticosteroids) had no effect on the plasma concentration of adiponectin (data not shown).
IR, measured as HOMA-IR, is considered the hallmark of MetS [19] . We found HOMA-IR higher among the participants with MetS than without (7.2 ± 5.8 vs. 5.7 ± 5.8), though the difference was not statistically significant in either univariate or multivariate analysis (p = 0.28 and p = 0.11, respectively). Other laboratory parameters are shown in table 2 . Although there was no difference in the levels of glycosylated hemoglobin, the 2-hour postchallenge glucose levels were considerably higher among the study participants with MetS than those without (133.5 ± 45.0 vs. 112.9 ± 35.1 mg/dl, β estimate 18.63, r 2 0.037, p = 0.056). During the follow-up, 10 patients developed NODAT, 7 patients suffered CVEs, 20 patients had acute rejection and 8 kidney grafts were lost including 2 deaths with graft function. Table 3 shows the distribution of events between patients with and without MetS. Due to limited sample size with small numbers of individual events, we combined all patients with any event and used this as a composite endpoint. Patients with MetS at 11 weeks were more likely to have an event during subsequent follow-up than patients without MetS (61. Values are means ± SD or n (%). iPTH = Intact parathyroid hormone; OGTT = oral glucose tolerance test.
on the other hand, were not independently associated with future event risk (data not shown). Renal function was not statistically different between the groups.
Discussion
We have previously shown that MetS is highly prevalent early after kidney transplantation among nondiabetic patients and was associated with abnormal glucose homeostasis [15] . In the current study, we show that patients with MetS early posttransplantation have significantly lower plasma levels of 25[OH]D and adiponectin. However, it is the presence of MetS, not the lower levels of 25[OH]D and adiponectin, that was independently associated with the risk of future clinical events.
MetS has been associated with increased risk of diabetes mellitus and CVEs in the general population. The pathogenic mechanism underlying such association includes IR likely due to the presence of low-grade chronic inflammation, deficiency in certain nutritional and/or hormonal elements, such as vitamin D and adiponectin [8, 11, [19] [20] [21] . Inadequate blood levels of vitamin D are common in the general population and present among 80-97% of stable kidney transplant patients [5, 7, 11] . Vitamin D deficiency not only causes impairment in calcium and bone metabolism, but also increases risks of many chronic medical conditions in the general population [20, 22, 23] . In subjects with MetS, lower levels of vitamin D predicted all-cause and cardiovascular disease mortality [24] . Although our study did not find an independent negative association of vitamin deficiency/ insufficiency with negative clinical outcomes which could be related to the small sample size with limited follow-up, based on the magnitude of vitamin D deficiency/insufficiency, its association with MetS and its many putative salutary effects, the role of its supplementation should be investigated in the kidney transplant patient population.
Adiponectin is adipokine that positively affects lipid and glucose metabolism [9] . The plasma concentration of adiponectin is inversely correlated with the risk of impaired glucose tolerance and T2D, premature coronary artery disease and MetS [10, [12] [13] [14] 25] . Our study confirmed the previous findings of an independent association between hypoadiponectinemia and MetS. Furthermore, only 2 out of 5 elements of MetS, HDL-C levels and waist circumference showed a significant correlation with the plasma concentration of adiponectin. However, we could not demonstrate a significant association between plasma concentration of adiponectin and IR as previously reported [13, 25] . Furthermore, we found no influence of immunosuppressive drugs on the plasma concentration of adiponectin.
Our study has several important limitations. First, it is an observational study which precluded us from drawing any cause-effect relationship between the presence of MetS and the observed laboratory and clinical parameters. Second, our study involved only a small number of patients with relatively young age and short follow-up period, which could explain the fewer cases of CVEs observed and the lack of association between the lower levels of 25[OH]D and adiponectin and negative clinical outcomes. Alternatively, the lower levels of 25[OH]D and adiponectin could represent an epiphenomenon of MetS rather than potential mechanisms through which MetS exercises its negative clinical impact. Finally, we measured only serum concentrations of total adiponectin which does not discriminate highfrom low-molecule-weight forms and thus we were unable to determine which form of adiponectin was associated with MetS.
In conclusion, nondiabetic kidney transplant recipients with MetS have a low plasma concentration of 25 [OH]D and adiponectin. The presence of MetS early after transplantation was associated with inferior clinical outcomes during a relatively short follow-up period. Additional studies involving a larger kidney transplant patient population and with longer follow-up are needed to Values are means ± SD or n (%). CHF = Congestive heart failure; eGFR = estimated glomerular filtration rate; MI = myocardial infarction; NODAT = new-onset diabetes mellitus after transplantation. 1 Some patients had >1 event.
Kulshrestha/Ojo/Luan Am J Nephrol 2013;37:399-404 DOI: 10.1159/000349930 404 determine whether the reported association has an etiologic role and whether vitamin D supplementation or other therapeutic interventions can mitigate the high prevalence of MetS in the kidney transplant population and counteract its negative impact on long-term clinical outcomes.
